biobetter on IV. some good points, most have been mentioned already. Taking out MDVN would put 800 million in cash and future milestones and obligations back into the pocket of astellas. This and the royalty power of mdv3100 make a takeout a nobrainer. But looking at zytiga and casodex gives us a good idea of what mdv3100 is worth and that type of earnings power does not go unnoticed by any big pharma.
been short since the low 30s has to hurt a little, sorry about that. we have all been there.
how did that blue moon call work for you... good call )) INHX was snapped up at a 160% premium and they are not even PII )) But, you could have bought IDIX when I told you to and made some money?? You seem like the type that likes to stick to whatever you are doing regardless if it is working or not. Go with that.
So, so far I have told the board to buy IDIX MDVN and INHX. So, far you have told the board to short MDVN.